Sanofi and GSK make timely entrance to Europe's COVID-19 booster vaccine battle
There is a new COVID-19 booster vaccine in town, just in time for Europe’s fall and winter season.
While they may not have reached market with a vaccine at the height of the pandemic to compete with jabs from the likes of Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), AstraZeneca (LSE: AZN) and Moderna (Nasdaq: MRNA), European pharma heavyweights Sanofi (Euronext: SAN) and GSK (LSE: GSK) have got there with a booster just in time for Europe’s upcoming colder months.
Their vaccine, VidPrevtyn Beta, is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe and was developed with US government funding. The approval was expected following a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze